Point of View
Antihypertensive Therapy -Going to the Heart of the Matter Franz H. Messerli, MD T he heart is but one of several target organs that is damaged by long-standing arterial hypertension. Unlike the diagnosis of functional and structural changes in the brain and kidneys the diagnosis of such changes in the heart can be made early and quantified accurately at the bedside by echocardiography, Holter monitoring, and radionuclide studies. In hypertension, the heart not only suffers from elevated arterial pressure (as a target organ), but it also generates the force needed to keep arterial pressure at these elevated levels. This dual role is of central importance in understanding the pathogenesis and the specific treatment of hypertensive heart disease. Clearly, such specific treatment should not only abolish the main pathogenetic factor (i.e., elevated arterial pressure) but also prevent or lead to a reversal of cardiac structural and functional changes that are the result of long-standing arterial hypertension. What then are the major sequelae of long-standing arterial hypertension in the heart? Cardiac Sequelae of Long-standing Hypertension Left Ventricular Hypertrophy
The main structural adaptation to an increased pressure load consists in concentric left ventricular hypertrophy (LVH), that is, an increase in wall thickness at the expense of chamber volume.1-4 However, an increase in arterial pressure may also be sustained by enhanced left ventricular contractility with little or no LVH.56 Conversely, hypertensive patients with concomitant volume overload states such as obesity develop predominantly eccentric LVH, that is, wall thickening and chamber dilation. 7, 8 Myocardial structural adaptation of hypertensive cardiovascular disease occurs early in the course of disease, and increased wall thickening can be found even in adolescents whose blood pressure is between the 75th and the 95th percentile for age, which are values considered within the normal range in adults.9,10 Impaired left ventricular filling, because of decreased relaxation in early diastole, is often pre- The sent in hypertensive patients before other arbitrary criteria of LVH are present, such as posterior wall thickness exceeding 1.1 cm, a ventricular mass exceeding an arbitrary value of 134 g/m2, or equally arbitrary voltage and vector criteria on the electrocardiogram. [11] [12] [13] [14] [15] In early hypertensive heart disease, impaired filling is predominantly caused by decreased relaxation during early diastole,16-18 whereas in more severe hypertensive heart disease, compliance during late diastole becomes impaired because of an increase in myocardial wall thickness.
The prevalence of LVH is greatly affected by age, and after the age of 65 years, more than 50% of patients with mild essential hypertension may have echocardiographic evidence of LVH.19,20 We recently reported a close correlation between 24-hour urinary sodium excretion levels and left ventricular mass in patients with essential hypertension, indicating that a high salt intake may facilitate the development of LVH, and conversely, a low salt diet could prevent or slow down this process. 21 The Framingham Study has clearly indicated that LVH according to electrocardiographic or echocardiographic criteria can no longer be considered a benign compensatory process. Independent of the degree of hypertension, LVH importantly increases cardiovascular morbidity and mortality.22-24 Recent data have documented that patients who have evidence of LVH by echocardiographic criteria share the same unfavorable prognosis.25 Clearly, the occurrence of LVH must be considered an ominous prognostic sign that greatly increases a given patient's risk for sudden death, congestive heart failure, and coronary artery disease. What are the mechanisms that connect LVH with an increased cardiovascular morbidity and mortality?
Ventricular Dysrhythmias
We have documented that patients with LVH (by electrocardiographic criteria) have a distinctly higher prevalence of premature ventricular contractions and more serious arrhythmias than do patients without LVH or normotensive subjects.26 Similarly, obese patients with eccentric LVH (increased wall thickness and chamber dilatation) exhibited increased ventricular ectopy when compared with obese patients without LVH or with lean subjects.27 Recent data2829 have corroborated and expanded our find-ings, thereby further attesting to the arrhythmogenicity of the hypertrophied myocardium even, at least in one study,29 in the presence of normal coronary arteries. The exact electrophysiologic mechanism by which an increase in left ventricular mass leads.to ectopy is unknown. Conceivably, the distorted myocardial structure caused by LVH may interfere with homogeneous impulse propagation, give rise to reentry mechanisms, and thereby become arrhythmogenic.30 Indeed, McLenachan et a131 demonstrated an excess of fibrosis and interstitial tissue in endomyocardial biopsy samples from patients who had severe LVH, normal coronary arteries, and episodes of ventricular tachycardia. In a recent electrophysiologic study, nonsustained ventricular tachycardia was induced in three of six patients with LVH according to echocardiographic and electrocardiographic criteria, whereas the same stimulus failed to induce ventricular tachycardia in patients with echocardiographically indicated LVH only or without LVH.32 Although a relation between increased ventricular ectopy and sudden death is far from established, it seems logical to assume that within a population that has been documented to be at risk (i.e., patients with LVH), those persons who have the highest grades of electric instability of the ventricle may also have the highest risk of more serious arrhythmias and sudden death.
Myocardial Ischemia
LVH is not only associated with an increase in ventricular ectopy, but it is also a predisposing condition to myocardial ischemia. Five pathogenetic mechanisms may lead from hypertension and LVH to myocardial ischemia33-36: 1) An elevation in arterial pressure will (if not offset by appropriate LVH) increase left ventricular wall stress, wall tension, and stroke work, thereby augmenting myocardial oxygen demand.37 2) An increase in myocardial mass that has occurred as an adaptation to an increased pressure load will, by itself, require more tissue perfusion.
3) The arteriosclerotic changes be found in vascular beds with low pressure (pulmonary circulation, poststenotic arterial segments). 5) Finally, it must be emphasized that the presence of LVH is not a prerequisite for the occurrence of angina in hypertensive patients without coronary disease. Myocardial ischemia due to an abnormally elevated resistance of the coronary microvasculature ("microvascular angina") has recently been documented in hypertensive patients without LVH. 40 Myocardial ischemia and, as a consequence, angina pectoris are therefore common sequelae of long-standing hypertension. Indeed, the Framingham Heart Study documented that the risk of acute myocardial infarction and angina pectoris increased sixfold to eightfold with the occurrence of LVH.23
Congestive Heart Failure As arterial hypertension becomes progressively more severe, the heart, despite adaptive hypertrophy, is less able to carry the burden of an ever-increasing afterload. Congestive heart failure with its dire consequences eventually ensues. The left chamber becomes dilated, and cardiac output falls. Vasoconstriction, mediated by an increased activity of the renin-angiotensin system, as well as the sympathetic nervous system, attempts to maintain arterial pressure at its preset levels. Clearly, the presence of latent or overt myocardial ischemia will further impair the pump function and accelerate the fall in contractility. However, a decline in systolic function is not always the sole culprit leading to pump failure in essential hypertension. For even in the presence of normal systolic function, impaired ventricular filling as the result of impaired relaxation and increased chamber stiffness can lead to clinically manifest heart failure.4' Topol et a142 described a subset of elderly hypertensive patients with heart failure whose conditions were characterized by excessive ventricular emptying by a small chamber volume and by impaired early diastolic filling. Whether systolic or diastolic dysfunction is more important or prevalent in the pathogenesis of congestive heart failure in patients with longstanding hypertension remains to be documented.
Congestive heart failure is a common complication of untreated long-standing hypertension: Data from the Framingham cohort have shown that over 80% of patients with manifest congestive heart failure had elevated blood pressure values in the past.43
Cardiac Sequelae and Therapeutic Approach At least to the extent that antihypertensive drugs (irrespective of their blood pressure-lowering effects) affect the above-mentioned four cardiac sequelae (i.e., left ventricular hypertrophy, ventricular dysrhythmias, myocardial ischemia, and congestive heart failure), they clearly have to be considered when selecting therapy. Although all antihypertensive drugs will lower arterial pressure (by definition), their effects on LVH, ventricular ectopy, congestive heart failure, and coronary artery disease may sharply differ. In the following, the effects of antihy-FIGURE 1. Schematic ofleft ventricular hypertrophy, ventricular dysrhythmias, myocardial ischemia, and congestive heart failure, which are the four major cardiac sequelae of longstanding hypertension. Although the sequelae clearly influence each other (see arrows), they are considered as separate entities for the purpose of this discussion.
pertensive monotherapy on these four cardiac sequelae of arterial hypertension are discussed, and advantages and disadvantages of various antihypertensive drug classes are critically analyzed. For the purpose of this analysis, each of these cardiac sequelae will be considered as a separate clinical entity, although clearly they are pathogenetically interrelated ( Figure 1 ). Total cholesterol and triglyceride levels have been documented to increase when thiazide diuretics are given, whereas high density lipoprotein (HDL) levels tend to fall (for reviews, see References 55 and 56). These changes have been reported to be most pronounced during the first few weeks of therapy and seem to become somewhat less important with prolonged therapy.
In contrast, impairment of glucose tolerance has been documented to become more severe with prolonged therapy, as was shown in patients who were receiving thiazides for up to 7 years.57-59 Once diuretic therapy was discontinued, the impaired glucose tolerance reverted to normal, clearly indicating that it was not the result of either progressive aging or an increase in adipose tissue. 59 An increase in uric acid commonly occurs with diuretic therapy, probably because of a fall in renal blood flow and a reduction in uric acid clearance. 60 Although hyperuricemia has been suggested to be a risk factor for coronary artery disease, it remains highly questionable whether diuretic-induced mild hyperuricemia must be considered as a risk as well.
Thus, when a thiazide diuretic is selected as the first-line antihypertensive agent, only one cardiac sequela of hypertension potentially improves (congestive heart failure as long as it is not due to predominantly diastolic dysfunction), one (3-blockers become considerably less attractive because they merely shift the patient from one pathologic state (elevated total peripheral resistance and normal cardiac output) to another one (same or higher levels of peripheral resistance and a low cardiac output), the long-term consequences of which are ill defined. In young patients with borderline and early established hypertension, who are hemodynamically characterized by an increase in heart rate and cardiac output, ,/-blockers remain an excellent choice. ,3-Blockers have been documented to reduce LVH in parallel with the fall in arterial pressure.69-71 Their effect-on ventricular ectopy is not entirely clear, although one would expect ventricular ectopy to decrease in parallel with the decrease in left ventricular mass. Of course, /8-blockers are good agents for patients concomitantly suffering from myocardial ischemia, because they decrease heart rate and arterial pressure and thereby reduce the double product and myocardial oxygen demand. The cardioprotective effect of timolol and certain other /3-blockers for secondary prevention of myocardial infarction has been extensively documented.72-75 However, these /3-blockers should be used only with great caution in the elderly hypertensive patient who is hemodynamically characterized by a low cardiac output and a high peripheral resistance,19 and they should be avoided altogether in patients with latent or overt congestive heart failure resulting from systolic dysfunction. In contrast, /3-blockers may be useful in some patients for the treatment of congestive heart failure from diastolic dysfunction. Thus, /3-blockers prevent or reverse two cardiac sequelae of hypertension (LVH and myocardial ischemia), possibly improve the third (ventricular dysrhythmias), and either worsen or improve the fourth (congestive heart failure) depending on Whereas clonidine may exert some negative inotropic properties, methyldopa seems to have little effect, and prazosin, as well as other peripherally acting agents, may even unload the left ventricle and thereby favorably influence the hemodynamic condition, at least over a short period of time.
Thus, centrally acting agents reduce LVH and probably improve ventricular dysrhythmias but have little effect on myocardial ischemia and congestive heart failure. The peripherally acting agents may reduce LVH or LVH-associated dysrhythmias, may be useful in congestive failure, and may exert some preventive effect on myocardial ischemia by virtue of their lipid-lowering properties.
Angiotensin Converting Enzyme Inhibitors and Calcium Channel Blockers
Angiotensin converting enzyme inhibitors and calcium channel blockers are relatively new in the antihypertensive arsenal. Angiotensin converting enzyme inhibitors are somewhat more effective in the younger, white patient81'82 (characterized by an activated renin-angiotensin system), whereas blood pressure response to calcium channel blockers has been shown to increase with age in the experience of some,83 but not all,84 investigators. In contrast to the use of angiotensin converting enzyme inhibitors, no racial difference in blood pressure responsiveness has been documented with use of calcium channel blockers. 85 Both drug classes seem to reduce LVH in parallel with their antihypertensive effect. 86 In patients with arterial hypertension and congestive heart failure, angiotensin converting enzyme inhibitors are clearly the drugs of choice. In these patients, a
short-acting drug (such as captopril) has been reported to be preferable to a long-acting compound, at least initially.100 However, the first study showing that angiotensin converting enzyme inhibition prolongs life in patients with class IV congestive failure was performed with enalapril.10' The unloading effect of calcium entry blockers often,102-104 but not always,105 overrides the direct negative inotropic effect of these drugs, and some of these agents have been used successfully in some patients with hypertension and congestive heart failure. A particular point in this case must be made in patients suffering from congestive failure on the basis of predominantly diastolic dysfunction (impaired left ventricular filling). Recent data have documented that calcium channel blockers improve ventricular relaxation in early diastole, restoring ventricular filling toward normal values.'06-108 Ventricular filling was already improved after intravenous applications of verapamil, indicating that this effect is independent of myocardial structural changes. Conceivably, calcium channel blockers have a dual effect on ventricular filling: initially, they improve early diastolic relaxation; with time, they also improve late diastolic compliance as a result of their LVH-reducing properties. Thus, it seems fair to state that calcium channel blockers, as well as angiotensin converting enzyme inhibitors, potentially improve all four cardiac sequelae of essential hypertension: LVH, ventricular dysrhythmias, myocardial ischemia, and congestive heart failure. However, this improvement varies from one drug to the other and is clearly not equipotent for all four sequelae. It is, therefore, not surprising that both of these drug classes have evolved within a very short period of time to become the most attractive agents currently used for the first-line treatment of essential hypertension.
Conclusions
Cardiac target organ damage from long-standing hypertension can be diagnosed early and quantified accurately by echocardiography, Holter monitoring, and radionuclide studies. The four commonly encountered cardiac sequelae of long-standing essential hypertension are left ventricular hypertrophy, ventricular dysrhythmias, myocardial ischemia, and congestive heart failure. Left ventricular hypertrophy, even though clinically silent, has an ominous prognosis and is, independent of arterial pressure, a harbinger of sudden death, myocardial infarction, congestive heart failure, and morbidity and mortality from other cardiovascular etiologies. Although these four cardiac sequelae may not always be clinically overt in a given patient, they are a foundation on which the therapeutic approach should be based 
